The new regulatory professionalism drive sweeping over the global medtech and pharmaceutical sectors will lead to better value for all health care stakeholders. This is of particular relevance in regions such as Asia, where regulatory manpower is often at low levels.
Regulatory affairsroles are the means by which companies ensure that they comply with the regulations and laws pertaining to their business. These roles are vital in making safe and effective health care products available worldwide.
The responsibilities of an RA executive often begin right at the start of a product’s R&D phase, and continue through...
BMS has launched a new cancer drug access program for low-to-middle income countries, focusing on addressing health inequities and widening accessibility.
Taylor Wessing investment partners share their thoughts about market trends, the surge in AI interest and the new UK government’s approach to the life sciences agenda.
The recent Women in Advanced Therapies Global event, delivered via an interactive 24-hour platform, hosted a number of biopharma speakers who drew on personal and industry-wide experiences, all aligned by a desire to break biases.
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
